FRANKFURT (dpa-AFX) - Schott Pharma shareholders were once again able to enjoy a record high on Thursday. With a rise to 38.00 euros, the shares of the Mainz-based pharmaceutical supplier clearly left the previous day's record high behind. Most recently, they were among the biggest winners in the SDax with a plus of 4.44% to 37.60 euros.

The company's still young stock market history is a success. On September 28, the Mainz-based company took the plunge onto the trading floor - since then, the share price has risen by up to almost 41 percent compared to the issue price of 27 euros. The index of smaller German companies, in which Schott Pharma was included in mid-December, has risen by a good ten percent in the same period.

The company, which manufactures glass tubes, vials and syringes for pharmaceuticals, is benefiting from important megatrends in the pharmaceutical industry. These include, first and foremost, the mRNA active ingredients that became known during the coronavirus pandemic and so-called GLP-1 drugs for weight loss. Experts are predicting a boom for both technologies.

In the current year, the Mainz-based company is aiming for an increase in sales and high investments in the millions despite the continuing headwinds from high energy prices and international price and competitive pressure. Schott Pharma is currently valued at around 5.7 billion euros on the stock exchange. The main shareholder is Schott AG. The specialty glass manufacturer holds 77 percent of the shares in Schott Pharma./gl/zb/jha/